newdrugapprovals.org
FDA approves first treatment Libtayo (cemiplimab-rwlc) for advanced form of the second most common skin cancer
FDA approves first treatment for advanced form of the second most common skin cancer New drug targets PD-1 pathway The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) inj…